Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plogosertib - Cyclacel Pharmaceutical

Next Previous
Search
Drug Profile

Plogosertib - Cyclacel Pharmaceutical

Alternative Names: CY-140; CYC-140

Latest Information Update: 11 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Developer Cyclacel Pharmaceuticals; M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Solid tumours
  • Phase I Leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 11 Dec 2024 Plogosertib is still in phase-I development in Leukaemia (Late-stage disease, Monotherapy, Refractory metastatic disease, Second-line therapy or greater) in USA (PO) and phase-I development in Myelodysplastic-syndromes (Late-stage disease, Monotherapy, Refractory metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03884829)
  • 26 Jun 2024 Cyclacel Pharmaceutical receives receipt of a notice of the intention to grant a patent covering claims to novel pharmaceutical compositions for plogosertib in European union
  • 19 Oct 2023 Cyclacel Pharmaceuticals terminates phase-I clinical trials in Leukaemia and Myelodysplastic syndromes (Late-stage disease, Monotherapy, Refractory metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03884829)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top